COR on NYSE

Cencora

Logo: Cencora, Public domain, via Wikimedia Commons6

American healthcare company

Cencora, Inc., formerly known as AmerisourceBergen, is an American drug wholesale and distribution company and a contract research organization, that was formed by the merger of Bergen Brunswig and AmeriSource in 2001. It was renamed to Cencora in 2023. Cencora is one of the largest pharmaceutical companies in the world and distributes generic pharmaceuticals, over-the-counter healthcare products, as well as home healthcare supplies and equipment.3 Its chief executive is Steven H. Collis (since 2011).1 It employed about 44,000 people in 2022.1 Its revenue was $239 billion in 2022.1 Wikipedia text CC BY-SA 4.0

$340.08 down 3.19 (0.93%)Price as of Oct 21, 2026 at 18:59 UTC

Last updated Oct 21, 2026.

Overview

$321.3BRevenue, fiscal 20257
$1.6BNet income, fiscal 20257
2001Founded1

Compare with McKesson Corporation, Cardinal Health or Herbalife, or pick any stock.

  • TickerCOR on NYSE1
  • Industrypharmaceutical industry1
  • HeadquartersChesterbrook1
  • Websitewww.cencora.com
  • Legal formDelaware corporation1
  • Incorporated inDE8
  • Business address1 West First Avenue, Conshohocken, Pa 194288
  • Filer categoryLarge accelerated filer8
  • LEIAI8GXW8LG5WK7E9UD0864
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 33687474
Cencora-headquarters-by-bill-cramer
Photo: BillCramer, CC BY-SA 4.0, via Wikimedia Commons11

Cencora, Inc., formerly known as AmerisourceBergen, is an American drug wholesale and distribution company and a contract research organization, that was formed by the merger of Bergen Brunswig and AmeriSource in 2001. It was renamed to Cencora in 2023. Cencora is one of the largest pharmaceutical companies in the world and distributes generic pharmaceuticals, over-the-counter healthcare products, as well as home healthcare supplies and equipment. The company is headquartered in Conshohocken, Pennsylvania, part of the Philadelphia metropolitan area.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

3.6%Gross margin7
0.8%Operating margin7
0.5%Net margin7
9.3%Revenue growth, 20257
103.1%Return on equity7
5.00×Debt to equity7
$3.2BFree cash flow7

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

U.S. Healthcare Solutions brought in 91% of the revenue Cencora broke down this way in fiscal 2025.

  1. U.S. Healthcare Solutions$291.0B791%up 10% from 2024
  2. International Healthcare Solutions$30.4B79%up 6% from 2024
Business segments by year
Business segments202320242025
U.S. Healthcare Solutions$234.8B$265.3B$291.0B
International Healthcare Solutions$27.4B$28.6B$30.4B

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue96¢$309.9B
  • Selling, general and admin2¢$6.5B
  • Other costs1¢$2.7B
  • Income tax0¢$690.5M
  • Profit0¢$1.6B

Out of $321.3B in revenue.7

Where each dollar of operating cash went, fiscal 2025

  • Capital spending17¢$668.0M
  • Dividends paid11¢$437.1M
  • Share buybacks11¢$435.5M
  • Kept or used elsewhere60¢$2.3B

Out of $3.9B of cash from operations.7

Financial statements

Revenue12131415167$321.3B in 2025+91% since 2018
0$100.0B$200.0B$300.0B$400.0B2018: $167.9B$167.9B20182019: $179.6B$179.6B2019+7%2020: $189.9B$189.9B2020+6%2021: $214.0B$214.0B2021+13%2022: $238.6B$238.6B2022+11%2023: $262.2B$262.2B2023+10%2024: $294.0B$294.0B2024+12%2025: $321.3B$321.3B2025+9%
Gross profit12131415167$11.5B in 2025+149% since 2018
0$5.0B$10.0B$15.0B2018: $4.6B$4.6B20182019: $5.1B$5.1B2019+11%2020: $5.2B$5.2B2020+1%2021: $6.9B$6.9B2021+34%2022: $8.3B$8.3B2022+19%2023: $9.0B$9.0B2023+8%2024: $9.9B$9.9B2024+11%2025: $11.5B$11.5B2025+16%
Operating income12131415167$2.6B in 2025+82% since 2018
-$6.0B-$4.0B-$2.0B0$2.0B$4.0B2018: $1.4B$1.4B20182019: $1.1B$1.1B2019−23%2020: -$5.1B-$5.1B20202021: $2.4B$2.4B20212022: $2.4B$2.4B2022+1%2023: $2.3B$2.3B2023−1%2024: $2.2B$2.2B2024−7%2025: $2.6B$2.6B2025+21%
Net income12131415167$1.6B in 2025−6% since 2018
-$4.0B-$2.0B0$2.0B2018: $1.7B$1.7B20182019: $855.4M$855.4M2019−48%2020: -$3.4B-$3.4B20202021: $1.5B$1.5B20212022: $1.7B$1.7B2022+10%2023: $1.7B$1.7B2023+3%2024: $1.5B$1.5B2024−14%2025: $1.6B$1.6B2025+3%

Every line of the income statement as filed: the last 3 fiscal years, latest first.7

Period ending2025-09-302024-09-302023-09-30
Revenue$321.3B$294.0B$262.2B
Cost of goods sold$309.9B$284.0B$253.2B
Gross profit$11.5B$9.9B$9.0B
Distribution, selling, and administrative$6.5B$5.7B$5.3B
Depreciation$494.1M$428.5M$410.3M
Amortization$556.9M$663.5M$553.6M
Litigation and opioid-related expenses (credit), net$60.7M$227.1M-$24.7M
Acquisition-related deal and integration expenses$291.0M$103.0M$139.7M
Restructuring and other expenses$229.4M$233.6M$229.9M
Goodwill impairment$723.9M$418.0M$0
Operating income$2.6B$2.2B$2.3B
Other loss (income), net$78.7M$14.3M-$49.0M
Interest expense, net$291.5M$157.0M$228.9M
Income before income taxes$2.3B$2.0B$2.2B
Income tax expense$690.5M$484.7M$428.3M
Net income$1.6B$1.5B$1.7B
Net (income) loss attributable to noncontrolling interests-$13.6M-$10.2M$12.7M
Net income attributable to Cencora, Inc.$1.6B$1.5B$1.7B
Basic (in usd per share)$8.02$7.60$8.62
Diluted (in usd per share)$7.96$7.53$8.53
Basic (in shares)193.8M shares198.5M shares202.5M shares
Diluted (in shares)195.2M shares200.3M shares204.6M shares

Compare Cencora with another company

Corporate structure

Cencora sits at the top of its group. 27 entities, 8 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Cencora

  • Cencora Conshohocken, Pennsylvania, United States
    • Alliance Healthcare Subsidiary
    • AB FINCO LTD Subsidiary · Woking, United Kingdom
    • AB Singapore Investments Pte. Ltd. Subsidiary · Singapore
    • AH UK Holdco 1 Limited Subsidiary · United Kingdom
    • ALLIANCE HEALTHCARE S.R.O Subsidiary · Prague, Czechia
    • Amerisource Receivables Financial Corporation Subsidiary · Delaware, United States
    • AmerisourceBergen Drug Corporation Subsidiary · Delaware, United States
    • AmerisourceBergen Global Holdings GmbH Subsidiary · Switzerland
    • AmerisourceBergen Global Manufacturer Services GmbH Subsidiary · Switzerland
    • AmerisourceBergen Group GmbH Subsidiary · Switzerland
    • AmerisourceBergen International B.V. Subsidiary · Netherlands
    • AmerisourceBergen International Holdings LLC Subsidiary · Delaware, United States
    • AmerisourceBergen Luxembourg S.a.r.L. Subsidiary · Luxembourg
    • AmerisourceBergen Services Corporation Subsidiary · Delaware, United States
    • AmerisourceBergen Sourcing, LLC Subsidiary · Delaware, United States
    • AmerisourceBergen Specialty Group, LLC Subsidiary · Delaware, United States
    • AmerisourceBergen UK Holdings Ltd Subsidiary · United Kingdom
    • ASD Specialty Healthcare, LLC Subsidiary · California, United States
    • BEACHCOURSE LIMITED Subsidiary · Woking, United Kingdom
    • BPL Group, LLC Subsidiary · Delaware, United States
    • Cencora Global Procurement Limited Subsidiary · Ireland
    • Cencora International Financing Holdings LLC Subsidiary · Delaware, United States
    • Cencora International Holdings Inc. Subsidiary · Delaware, United States
    • International Physician Networks, L.L.C. Subsidiary · Delaware, United States
    • OTC DIRECT LIMITED Subsidiary · Chessington, United Kingdom
    • and 1 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Cencora reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$5.7B7 Sep 30, 2025$5.2B7 Sep 30, 2024+9.9%
Accumulated depreciation$3.2B7 Sep 30, 2025$3.0B7 Sep 30, 2024+5.3%
Property and equipment, net$2.5B7 Sep 30, 2025$2.2B7 Sep 30, 2024+16.4%
Operating-lease assets (leased space)$1.5B7 Sep 30, 2025$1.1B7 Sep 30, 2024+35.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$4.4B7 Sep 30, 2025$3.1B7 Sep 30, 2024+39.1%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$13.7B7 Sep 30, 2025$9.3B7 Sep 30, 2024+46.8%
Intangible assets, net (excluding goodwill)$3.8B7 Sep 30, 2025$4.0B7 Sep 30, 2024−5.7%
Accumulated amortization$3.0B7 Sep 30, 2025$2.4B7 Sep 30, 2024+24.7%

Inventory

ItemLatestA year beforeChange
Inventory, total$20.5B7 Sep 30, 2025$19.0B7 Sep 30, 2024+7.9%

Properties, in its own words

As of September 30, 2025, we conducted our business from office and operating facilities at owned and leased locations throughout the United States (including Puerto Rico) and select global markets. We lease a facility in Conshohocken, Pennsylvania for our corporate headquarters.

U.S. Healthcare Solutions’ human health distribution businesses have a robust distribution facility network in the United States. Significant leased facilities are located in Puerto Rico plus the following states: Arizona, California, Colorado, Florida, Georgia, Hawaii, Indiana, Kentucky, Minnesota, Mississippi, New York, North Carolina, Ohio, Utah, and Washington. Owned facilities are located in the following states: Alabama, California, Illinois, Massachusetts, Michigan, Missouri, Ohio, Pennsylvania, Texas, and Virginia.

The rest of Item 2

As of September 30, 2025, our animal health business operations were conducted in the United States and in the United Kingdom. Leased facilities are located in California, Colorado, Florida, Idaho, Indiana, Kansas, Massachusetts, Minnesota, North Carolina, Pennsylvania, Texas, Washington, and internationally in the United Kingdom. Significant owned facilities are located in Alabama, Idaho, Texas, and Virginia and internationally in the United Kingdom. Its headquarters is located in Idaho.

As of September 30, 2025, the International Healthcare Solutions distribution operations were conducted in Canada, the Czech Republic, France, Lithuania, Netherlands, Norway, Romania, Spain, Turkey, and the United Kingdom. Its global

specialty transportation and logistics operating facilities are located in over 50 countries. The International Healthcare Solutions businesses have leased and owned properties.

We consider our operating and office properties to be in satisfactory condition.

Item 2 of the 10-K filed Nov 25, 2025.21

Stakes and holdings (Wikidata)

Things Wikidata records the company as owning, with the share when stated.1

The story

AmerisourceBergen was formed in 2001 following the merger of AmeriSource Health Corporation and Bergen Brunswig Corporation. David Yost was CEO of Amerisource prior to the merger and remained in the position after the companies merged.

AmerisourceBergen has 26 pharmaceutical distribution centers in the US, nine distribution centers in Canada, four specialty distribution centers in the US, and over 1 million square feet of packaging production capacity in the US and the UK. With the addition of World Courier, the largest specialty courier company in the world, over 150 company-owned offices around the globe were added to the company.

AmerisourceBergen operates its pharmaceutical distribution business under four primary units: AmerisourceBergen Drug Corporation (ABDC), AmerisourceBergen Specialty Group (ABSG), AmerisourceBergen Consulting Services (ABCS) and World Courier. In March 2016, pharmacy Walgreens Boots Alliance Inc. announced it would exercise an option to purchase 22.7 million shares of AmerisourceBergen stock and thereby control 15% of the company.

In 2012, the firm was the largest by revenue based in Pennsylvania. The company changed its name to Cencora as of August 30, 2023 and began trading on the New York Stock Exchange under the new ticker symbol "COR". In May 2024, Cencora disclosed it had been the subject of a cyber incident in which patient information was exposed.

Products

They provide drug distribution and consulting related to medical business operations and patient services. They also distribute a line of brand name and generic pharmaceuticals, over-the-counter (OTC) health care products and home health care supplies and equipment to health care providers throughout the United States, including acute care hospitals and health systems, independent and chain retail pharmacies, mail-order facilities, physicians, clinics and other alternate site facilities, as well as nursing and assisted living centers. They also provide pharmaceuticals and pharmacy services to long-term care, workers' compensation and specialty drug patients.

AmerisourceBergen handles about 20% of all of the pharmaceuticals sold and distributed throughout the United States and ranked 10th on the Fortune 500 list for 2020 with over $179 billion in annual revenue.

Good Neighbor Pharmacy

Good Neighbor Pharmacy is an American retailers' cooperative network of more than 3,400 independently owned and operated pharmacies. It has a business affiliation with AmerisourceBergen, which sponsors the network and owns the name "Good Neighbor Pharmacy." Good Neighbor Pharmacy is the sponsor for "ThoughtSpot," the annual trade show held in both Orlando and Las Vegas.

Acquisition history

In 2011, the company acquired IntrinsiQ for $35 million and Premier Source for an undisclosed amount. In July, Steven Collis replaced Yost as CEO of the company.

Read the full text

In March 2012, AmerisourceBergen agreed to acquire World Courier Group Inc, a transportation and logistics provider for the biopharmaceutical industry, for $520 million.

In January 2015, the company bought MWI Veterinary for $2.5 billion. In October, they agreed to buy PharMEDium, a compounding drug company, for $2.58 billion.

On January 3, 2018, AmerisourceBergen acquired H. D. Smith, the largest privately held national pharmaceutical wholesaler in the U.S.

On June 2, 2021, AmerisourceBergen acquired Alliance Healthcare from Walgreens Boots Alliance for approximately $6.5 billion, made up of $6.275 billion in cash and 2 million shares of AmerisourceBergen common stock.

On January 2, 2025, Cencora acquired 85% of Retina Consultants of America for approximately $4.4 billion.

From Wikipedia’s article on Cencora, shared under CC BY-SA 4.0.9

Leadership

Who has led Cencora, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (46)

Products and brands

  • medication

Listed on Wikidata.1

Subsidiaries and ownership

Owners

Subsidiaries

Subsidiaries (Exhibit 21)

  • AB Singapore Investments Pte. Ltd. Singapore10
  • AH UK Holdco 1 Limited UK10
  • ASD Specialty Healthcare, LLC California10
  • Amerisource Receivables Financial Corporation Delaware10
  • AmerisourceBergen Drug Corporation Delaware10
  • AmerisourceBergen Global Holdings GmbH Switzerland10
  • AmerisourceBergen Global Manufacturer Services GmbH Switzerland10
  • AmerisourceBergen Group GmbH Switzerland10
  • AmerisourceBergen International B.V. Netherlands10
  • AmerisourceBergen International Holdings LLC Delaware10
  • AmerisourceBergen Luxembourg S.a.r.L. Luxembourg10
  • AmerisourceBergen Services Corporation Delaware10
  • AmerisourceBergen Sourcing, LLC Delaware10
  • AmerisourceBergen Specialty Group, LLC Delaware10
  • AmerisourceBergen UK Holdings Ltd UK10
  • BPL Group, LLC Delaware10
  • Cencora Global Procurement Limited Ireland10
  • Cencora International Financing Holdings LLC Delaware10
  • Cencora International Holdings Inc. Delaware10
  • International Physician Networks, L.L.C. Delaware10
  • World Courier Group S.à r.l. Luxembourg10

From Wikidata.1 The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Acquisitions

  1. 2023Acquired Alliance Healthcare1

Employees over time

  • 202244,0001

Former names

  • AMERISOURCEBERGEN CORPOct 19, 2001 to Aug 15, 20238
  • AMERISOURCE BERGEN CORPJun 5, 2001 to Oct 9, 20018

Timeline

  1. Sep 25, 20268-K Executive or director change; Regulation FD disclosure76
  2. Aug 14, 20268-K Executive or director change77
  3. Aug 12, 20268-K Regulation FD disclosure78
  4. Aug 5, 20268-K Results of operations; Regulation FD disclosure79
  5. Aug 5, 20268-K Entered a material agreement; New debt or obligation80
  6. Jun 15, 20268-K Executive or director change; Regulation FD disclosure81
  7. May 29, 20268-K Executive or director change; Regulation FD disclosure82
  8. May 6, 20268-K Results of operations; Regulation FD disclosure83
  9. Mar 23, 20268-K Regulation FD disclosure84
  10. Mar 17, 20268-K Executive or director change; Regulation FD disclosure85
  11. Mar 6, 20268-K Shareholder vote86
  12. Feb 18, 20268-K Regulation FD disclosure; Other events87
  13. Nov 13, 2024New chief executive Robert P. Mauch becomes CEO22
  14. Aug 2023Went public Listed on NYSE1
  15. Jul 2011New chief executive Steven H. Collis becomes CEO1
  16. Feb 1, 2006New chief executive David Yost becomes CEO24
  17. 2001Founded Founded1
  18. May 28, 1996Went public Listed on NYSE1

Calendar

Coming up

  1. Nov 4, 2026 · Before the openReports results for the quarter ending Sep/2026 A year earlier it reported $3.84 a share, on Nov 5, 2025.88

When it reported results

  1. Aug 5, 2026Reported quarterly or annual results79
  2. May 6, 2026Reported quarterly or annual results83
  3. Feb 4, 2026Reported quarterly or annual results89
  4. Nov 5, 2025Reported quarterly or annual results90
  5. Aug 6, 2025Reported quarterly or annual results91
  6. May 7, 2025Reported quarterly or annual results92
  7. Feb 5, 2025Reported quarterly or annual results93
  8. Nov 6, 2024Reported quarterly or annual results94

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

687 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 104 major events, 385 insider forms, 27 large holders, 151 other. The latest 20:

  1. Oct 5, 20264 EDGAR
  2. Oct 5, 20264 EDGAR
  3. Oct 1, 20263 EDGAR
  4. Sep 25, 20268-K EDGAR
  5. Sep 17, 20264 EDGAR
  6. Sep 16, 2026144 EDGAR
  7. Sep 11, 2026144 EDGAR
  8. Sep 4, 2026144 EDGAR
  9. Sep 2, 20264 EDGAR
  10. Sep 1, 2026144 EDGAR
  11. Aug 25, 20264 EDGAR
  12. Aug 24, 2026144 EDGAR
  13. Aug 14, 20268-K EDGAR
  14. Aug 12, 20268-K EDGAR
  15. Aug 6, 2026144 EDGAR
  16. Aug 5, 202610-Q EDGAR
  17. Aug 5, 20268-K EDGAR
  18. Aug 5, 20268-K EDGAR
  19. Aug 4, 20264 EDGAR
  20. Aug 4, 20264 EDGAR

The 687 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

131 open-market trades by officers, directors and large owners since October 2021: 4 buys and 127 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 16, 2026GREENBERG LON RDirectorSale1,280$321.30$411.3KForm 4
Sep 1, 2026Krikorian LazarusSVP & Chief Accounting OfficerSale985$325.97$321.1KForm 4
Aug 24, 2026Campbell Elizabeth SExecutive Vice PresidentSale11,300$324.12$3.7MForm 4
Jun 22, 2026Tyler Lauren MDirectorBuy550$270.23$148.6KForm 4
Jun 18, 2026DURCAN DERMOT MARKDirectorBuy4,000$274.19$1.1MForm 4
May 28, 2026DURCAN DERMOT MARKDirectorBuy4,000$266.26$1.1MForm 4
Feb 20, 2026Mauch Robert P.President & CEOSale3,762$358.94$1.4MForm 4
Feb 18, 2026Mauch Robert P.President & CEOSale1,333$359.46$479.2KForm 4
Jan 20, 2026Mauch Robert P.President & CEOSale5,096$354.73$1.8MForm 4
Dec 19, 2025Campbell Elizabeth SExecutive Vice PresidentSale3,351$342.10$1.1MForm 4
Dec 19, 2025Battaglia SilvanaExecutive Vice PresidentSale1,677$345.00$578.6KForm 4
Dec 18, 2025Mauch Robert P.President & CEOSale5,096$343.45$1.8MForm 4
Dec 17, 2025Krikorian LazarusSVP & Chief Accounting OfficerSale4,031$343.24$1.4MForm 4
Nov 18, 2025Mauch Robert P.President & CEOSale5,096$366.64$1.9MForm 4
Oct 20, 2025Mauch Robert P.President & CEOSale5,097$326.80$1.7MForm 4
Oct 1, 2025Campbell Elizabeth SExecutive Vice PresidentSale1,886$313.28$590.8KForm 4
Sep 18, 2025Mauch Robert P.President & CEOSale5,097$290.00$1.5MForm 4
Sep 16, 2025COLLIS STEVEN HExecutive ChairmanSale31,350$289.86$9.1MForm 4
Aug 19, 2025COLLIS STEVEN HExecutive ChairmanSale14,579$289.98$4.2MForm 4
Aug 18, 2025Mauch Robert P.President & CEOSale4,968$293.53$1.5MForm 4

All 131 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Robert P. MauchPresident and Chief Executive Officer$1.4M$18.3M100
2025Steven H. CollisExecutive Chairman*$1.0M$9.7M100
2025James F. ClearyExecutive Vice President and Chief Financial Officer$926.1K$6.5M100
2025Elizabeth S. CampbellExecutive Vice President and Chief Legal Officer$769.2K$5.2M100
2025Silvana BattagliaExecutive Vice President and Chief Human Resources Officer$664.8K$3.7M100
2024Steven H. CollisExecutive Chairman*$1.5M$18.5M100
2024Robert P. MauchPresident and Chief Executive Officer$1.0M$9.3M100
2024James F. ClearyExecutive Vice President and Chief Financial Officer$885.9K$9.0M100
2024Elizabeth S. CampbellExecutive Vice President and Chief Legal Officer$722.0K$7.7M100
2024Silvana BattagliaExecutive Vice President and Chief Human Resources Officer$626.0K$5.3M100
2023Steven H. CollisExecutive Chairman*$1.4M$17.5M100
2023Robert P. MauchPresident and Chief Executive Officer$975.0K$7.7M100
2023James F. ClearyExecutive Vice President and Chief Financial Officer$795.0K$5.4M100
2023Elizabeth S. CampbellExecutive Vice President and Chief Legal Officer$670.0K$4.0M100
2023Silvana BattagliaExecutive Vice President and Chief Human Resources Officer$600.0K$3.0M100

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.18,213,783$5.2B0.1%−1,729,854
Vanguard Capital Management LLC12,378,943$3.5B0.1%+65,484
Vanguard Portfolio Management LLC9,611,756$2.7B0.1%+21,342
State Street Corp9,273,983$2.6B0.1%+83,432
Jpmorgan Chase & Co5,943,657$1.7B0.1%+1,058,179
Geode Capital Management, LLC5,454,888$1.5B0.1%−111,156
Boston Partners4,868,782$1.4B1.2%+385,965
Wellington Management Group Llp4,559,761$1.3B0.2%+11,149
Fmr LLC4,122,371$1.2B0.1%−2,563,898
Morgan Stanley4,086,271$1.2B0.1%−445,641
Bank Of America Corp /de/3,733,921$1.1B0.1%−404,467
Norges Bank2,473,825$700.0M0.1%New
Goldman Sachs Group Inc2,274,148$643.5M0.1%+61,260
Amundi2,229,326$630.9M0.2%+676,066
Northern Trust Corp2,158,939$610.9M0.1%−23,736
Invesco Ltd.2,021,234$572.0M0.0%−1,966,502
Capital Research Global Investors1,979,942$560.3M0.1%+20,292
Carmignac Gestion1,747,363$494.5M6.4%+646,112
Mitsubishi UFJ Asset Management Co., Ltd.1,709,563$483.8M0.3%+349,835
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC1,708,377$483.4M0.1%+91,814
Dimensional Fund Advisors LP1,640,452$464.2M0.1%+91,405
Mawer Investment Management Ltd.1,488,843$421.3M2.9%+457,680
Citadel Advisors LLC1,366,647$386.7M0.2%+568,820
Nordea Investment Management Ab1,341,795$376.1M0.3%+31,739
Wells Fargo & Company/mn1,285,421$363.7M0.1%−47,375

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

11 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
May 6, 2026Jared MoskowitzDemocratic, HouseSale$1,001 - $15,000−29.7%Report
May 6, 2026Jared MoskowitzDemocratic, HouseSale$1,001 - $15,000−29.7%Report
Mar 31, 2026Jared MoskowitzDemocratic, HouseBuy$1,001 - $15,000−10.1%Report
Mar 27, 2026Alan ArmstrongRepublican, SenateBuy$1,001 - $15,000−12.6%Report
Mar 23, 2026Jared MoskowitzDemocratic, HouseBuy$1,001 - $15,000−11.4%Report
Mar 23, 2026Jared MoskowitzDemocratic, HouseBuy$1,001 - $15,000−11.4%Report
May 12, 2025Jefferson ShreveRepublican, HouseSale$50,001 - $100,000+9.9%Report
Mar 27, 2025Greg LandsmanDemocratic, HouseSale$15,001 - $50,000+11.7%Report
May 29, 2024Greg LandsmanDemocratic, HouseBuy$15,001 - $50,000+8.9%Report
Nov 16, 2021Thomas R Carper, SenateSale$1,001 - $15,000−110.8%Report
Aug 4, 2021Thomas R Carper, SenateBuy$1,001 - $15,000+95.7%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How Cencora is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCencora, Inc.2
  • CIK0001140859
  • Employer ID (EIN)23-307939021
  • Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company21
  • Incorporated inDelaware21
  • Fiscal year endsSeptember 302
  • Industry code (SIC)5122 Wholesale-Drugs, Proprietaries & Druggists' Sundries2
  • SEC reviewing officeOffice of Trade & Services, Division of Corporation Finance2
  • Business address1 West First Avenue, Conshohocken, PA 194282
  • Phone610-727-70002
  • Shares outstanding190,827,165 as of Jul 31, 202619
  • Public float$37.9B as of Mar 31, 202521
  • AuditorErnst & Young LLP, Philadelphia, Pennsylvania PCAOB ID 42; it also attests to the company’s internal control over financial reporting21
  • On EDGAR sinceMay 23, 20012
  • Filings2,570 in all: 4 (1,415), 8-K (445), 144 (94), 10-Q (75), SC 13G/A (62), 3 (41), 11-K (34), 4/A (31)2
    All 57 form types

    UPLOAD (29), 425 (27), 10-K (25), DEF 14A (25), 424B3 (23), CORRESP (23), DEFA14A (19), SC 13D/A (19), SC 13G (18), SD (13), 424B5 (11), FWP (11), S-8 (11), 424B2 (9), 8-K/A (9), S-8 POS (9), SC TO-T/A (7), ARS (6), PRE 14A (6), S-3ASR (6), NO ACT (5), PX14A6G (5), S-4/A (5), 424B7 (4), POSASR (4), S-4 (4), SCHEDULE 13D/A (4), EFFECT (3), S-3 (3), SC TO-C (3), SCHEDULE 13G/A (3), 5 (2), 8-A12B (2), D/A (2), DEFR14A (2), POS AM (2), REGDEX (2), 10-K/A (1), 25-NSE (1), 3/A (1), 305B2 (1), CERT (1), CT ORDER (1), D (1), PX14A6N (1), S-3/A (1), SC 13D (1), SC TO-T (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Nov 25, 2025
    Quarterly report (10-Q) Aug 5, 2026
    Proxy statement (DEF 14A) Jan 22, 2026
    Latest 8-K (8-K) Sep 25, 2026

Securities registered for trading

ClassSymbolExchange
Common stock, par value $0.01 per shareCORNew York Stock Exchange
2.875% Senior Notes due 2028COR28New York Stock Exchange
3.625% Senior Notes due 2032COR32New York Stock Exchange

From the cover page of the 10-K filed Nov 25, 2025 (Section 12(b) of the Exchange Act).21

Risk factors and legal proceedings

The risks Cencora names in Item 1A of its 10-K filed Nov 25, 2025: 31 risks under these headings, as written.21

  • Business and Operational Risks
  • Our revenue, financial position, results of operations, and cash flows may suffer upon the loss, or renewal at less favorable terms, of a key customer or group purchasing organization.
  • The anticipated ongoing benefits of our relationship with Walgreens and Boots may not be realized.
  • A disruption in our distribution or generic purchasing services arrangements with Walgreens or WBAD could adversely affect our business and financial results.
  • Our results of operations and financial position may be adversely affected if we acquire or invest in businesses that do not perform as we expect or that are difficult for us to integrate.
  • Our business and results of operations may be adversely affected if we fail to manage and complete divestitures.
  • We face geopolitical and other risks associated with our international operations, which could materially adversely impact our financial position, results of operations, and cash flows.
  • We might be adversely impacted by fluctuations in foreign currency exchange rates.
  • We are subject to operational and logistical risks that might not be covered by insurance.
  • We are subject to industry risks that might not be covered by insurance nor indemnification obligations of our contracted parties.
  • We might be unable to successfully recruit and retain qualified employees.
  • The loss or disruption of information systems could disrupt our operations and have a material adverse effect on our business.
The other 20 risks
  • Industry and Economic Risks
  • Our results of operations could be adversely impacted by manufacturer pricing changes.
  • Competition and industry consolidation may erode our profit.
  • Our revenue and results of operations may suffer upon the bankruptcy, insolvency, or other credit failure of a significant customer or supplier.
  • Our stock price and our ability to access credit markets may be adversely affected by financial market volatility and disruption or a downgrade in our credit ratings.
  • Declining economic conditions could adversely affect our results of operations and financial position.
  • Litigation and Regulatory Risks
  • Increasing governmental efforts to regulate the pharmaceutical supply chain may increase our costs and reduce our profitability.
  • Legal, regulatory, and legislative changes with respect to coverage, reimbursement, pricing, and contracting may adversely affect our business and results of operations, including through declining reimbursement rates.
  • If we fail to comply with laws and regulations in respect of healthcare fraud and abuse, we could suffer penalties or be required to make significant changes to our operations.
  • Our business, results of operations, and cash flows could be adversely affected by legal proceedings.
  • Opioid-related legal proceedings and the Distributor Settlement Agreement that we have entered into could adversely impact our cash flows or results of operations.
  • Public concern over the abuse of medications could negatively affect our business.
  • Tax legislation or challenges to our tax positions could adversely affect our results of operations and financial position.
  • Violations of anti-bribery, anti-corruption, and/or international trade laws that we are subject to could have a material adverse effect on our business, financial position, and results of operations.
  • Any actual or perceived failure to adequately protect proprietary business information or personal data could result in claims of liability against us, damage our reputation or otherwise materially harm our business.
  • Our third-party business partners are vulnerable to cybersecurity risks, and any cyber incident affecting our third-party business partners could significantly disrupt our operations.
  • Any actual or perceived failure to protect our reputation could have a material adverse effect on our business and operations.
  • Our intellectual property rights may not provide meaningful commercial protection.
  • We have been and may in the future be adversely impacted by events outside of our control.
  • Our goodwill or long-lived assets may become impaired, which may require us to record a significant charge to earnings in accordance with generally accepted accounting principles.
  • Exclusive forum provisions in our amended and restated bylaws (“Bylaws”) could limit our stockholders’ ability to choose their preferred judicial forum for disputes with us or our directors, officers, or employees.

Legal proceedings

Legal proceedings in which we are involved are discussed in Note 12 (Legal Matters and Contingencies) and Note 13 (Antitrust Litigation Settlements) of the Notes to Consolidated Financial Statements appearing in this Annual Report on Form 10-K.

The opening of Item 3, Legal Proceedings.21

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
    Yahoo FinanceCOR quote
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
    Wikidata and SEC EDGARLorence Kim, Board member
  59. 59
    Wikidata and SEC EDGARDennis M. Nally, Board member
  60. 60
    Wikidata and SEC EDGAROrnella Barra, Board member
  61. 61
  62. 62
  63. 63
    Wikidata and SEC EDGARLon R. Greenberg, Board member
  64. 64
    Wikidata and SEC EDGARSteven H. Collis, Board member
  65. 65
    Wikidata and SEC EDGARKathleen W. Hyle, Board member
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
    Wikidata and SEC EDGARMichael J. Long, Board member
  74. 74
    Wikidata and SEC EDGARHenry W. McGee, Board member
  75. 75
    Wikidata and SEC EDGARJane E. Henney, Board member
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89
  90. 90
  91. 91
  92. 92
  93. 93
  94. 94
  95. 95
  96. 96
  97. 97
  98. 98
  99. 99
  100. 100